Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 9, 2023. The report discloses that senior executives will commence a series of meetings with the scientific and financial community beginning on this date. The company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol COCP.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a disclosure of upcoming investor relations activities rather than a financial results announcement.
Material Changes
No material changes to financial performance or operations are reported in this document. The primary event is the initiation of a corporate presentation tour.
Guidance, Outlook, and Management Commentary
Management is providing a corporate presentation (Exhibit 99.1) to be used during meetings with the scientific and financial community. The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. No specific forward-looking guidance or risk factors are detailed within the text of this 8-K.
Key Facts for Investor Verification
- Verify the content of the Corporate Presentation (Exhibit 99.1) for specific business updates, as the 8-K text itself contains no operational data.
- Confirm the trading status of COCP on The Nasdaq Capital Market.
- Note that the presentation materials are not legally "filed" under Section 18 of the Exchange Act.
- Identify James Martin as the Chief Financial Officer and Co-Interim Chief Executive Officer signing the report.